Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.1% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACOR
1976
DELISTED
Acorda Therapeutics
ACOR
| $2.83M | ﹤0.01% |
32,089
+234
| +0.7% | +$24.7K |
|
1977
iShares 0-5 Year TIPS Bond ETF
STIP
$15.8B
| $2.83M | ﹤0.01% |
27,600
+16,400
| +146% | +$1.66M |
|
|
FINV
1978
FinVolution Group
FINV
$1.15B
| $2.82M | ﹤0.01% |
1,560,479
+569,500
| +57% | +$949K |
|
|
EIDX
1979
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $2.81M | ﹤0.01% |
59,001
-10,000
| -14% | -$465K |
|
1980
Corvus Pharmaceuticals
CRVS
$1.12B
| $2.81M | ﹤0.01% |
1,031,900
+101,200
| +11% | +$299K |
|
1981
Global Indemnity Group
GBLI
$402M
| $2.8M | ﹤0.01% |
117,050
-26,714
| -19% | -$638K |
|
1982
Orion Group Holdings
ORN
$396M
| $2.79M | ﹤0.01% |
889,197
-50,600
| -5% | -$127K |
|
|
EXFO
1983
DELISTED
EXFO INC.
EXFO
| $2.79M | ﹤0.01% |
991,572
+11,159
| +1% | +$29.3K |
|
1984
State Street SPDR Nuveen ICE High Yield Municipal Bond ETF
HYMB
$3.17B
| $2.78M | ﹤0.01% |
+98,800
| New | +$2.68M |
|
1985
Nabors Industries
NBR
$1.27B
| $2.78M | ﹤0.01% |
75,214
-270,762
| -78% | -$7.78M |
|
1986
Avita Medical
RCEL
$135M
| $2.78M | ﹤0.01% |
91,100
+67,220
| +281% | +$2.06M |
|
|
FFG
1987
DELISTED
FBL Financial Group
FFG
| $2.78M | ﹤0.01% |
77,500
-34,600
| -31% | -$1.27M |
|
1988
Lightpath Technologies
LPTH
$651M
| $2.78M | ﹤0.01% |
831,465
+464,689
| +127% | +$1.06M |
|
|
MYOK
1989
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.77M | ﹤0.01% |
28,700
-21,400
| -43% | -$1.79M |
|
1990
Healthcare Services Group
HCSG
$1.6B
| $2.76M | ﹤0.01% |
112,864
-118,000
| -51% | -$2.79M |
|
1991
inTEST
INTT
$155M
| $2.76M | ﹤0.01% |
817,722
+21,515
| +3% | +$68.5K |
|
1992
FRP Holdings
FRPH
$428M
| $2.75M | ﹤0.01% |
135,600
+112,800
| +495% | +$2.34M |
|
1993
Vanguard Morningstar Total Stock Market ETF
VTI
$670B
| $2.74M | ﹤0.01% |
17,500
+8,700
| +99% | +$1.28M |
|
1994
Teekay Tankers
TNK
$2.75B
| $2.73M | ﹤0.01% |
213,165
-951,600
| -82% | -$16.8M |
|
1995
AMES National
ATLO
$271M
| $2.73M | ﹤0.01% |
138,400
-1,500
| -1% | -$29.3K |
|
|
MOFG
1996
DELISTED
MidWestOne Financial Group
MOFG
| $2.72M | ﹤0.01% |
136,100
-45,400
| -25% | -$876K |
|
1997
Urban One Class D
UONEK
$22.8M
| $2.72M | ﹤0.01% |
142,298
-4,840
| -3% | -$55.2K |
|
|
MTEM
1998
DELISTED
Molecular Templates, Inc.
MTEM
| $2.71M | ﹤0.01% |
+13,125
| New | +$3.05M |
|
|
BEDU
1999
DELISTED
Bright Scholar Education Holdings
BEDU
| $2.71M | ﹤0.01% |
86,300
+7,975
| +10% | +$227K |
|
|
GNTY
2000
DELISTED
Guaranty Bancshares
GNTY
| $2.7M | ﹤0.01% |
114,946
-2,124
| -2% | -$47.9K |
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.